Search hospitals

>

Nevada

>

Reno

Saint Mary's Regional Medical Center

Claim this profile

Reno, Nevada 89503

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

170 reported clinical trials

3 medical researchers

Photo of Saint Mary's Regional Medical Center in RenoPhoto of Saint Mary's Regional Medical Center in RenoPhoto of Saint Mary's Regional Medical Center in Reno

Summary

Saint Mary's Regional Medical Center is a medical facility located in Reno, Nevada. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Saint Mary's Regional Medical Center is involved with conducting 170 clinical trials across 343 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Samuel Chacon, MD.

Area of expertise

1

Lung Cancer

Global Leader

Saint Mary's Regional Medical Center has run 36 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I
2

Breast Cancer

Global Leader

Saint Mary's Regional Medical Center has run 29 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at Saint Mary's Regional Medical Center

Bladder Cancer

Breast Cancer

Lung Cancer

Esophageal cancer

Kidney Cancer

Bladder Carcinoma

Breast cancer

Gastric cancer

Testicular cancer

Prostate Cancer

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Image of trial facility.

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Mary's Regional Medical Center?